News

ArsenalBio and Bristol Myers Squibb Achieve Milestone to Advance Next-Generation T Cell Therapies for Solid Tumors

Arsenal Biosciences, a clinical-stage programmable cell therapy company focused on engineering advanced CAR T cell therapies for solid tumors, today announced that Bristol Myers Squibb has exercised its exclusive license option for ArsenalBio’s AB-4000 series, the lead collaboration program...

Vevo Therapeutics to Open Source Milestone Tahoe-100M Dataset

Vevo Therapeutics, a biotechnology company using its Mosaic technology and next-generation AI to uncover better drugs for more patients, announced today that it would open-source its historic Tahoe-100M dataset in collaboration with NVIDIA's biology foundation model research team. The NVIDIA team...

Alessa Therapeutics Announces First Patient Enrolled in the Enolen Study for Localized Drug Delivery for Prostate Cancer

Alessa Therapeutics, a privately held drug development company developing an innovative and proprietary localized drug delivery technology for the treatment of prostate disease, announced the enrollment of the first patient in the company’s Enolen® clinical study at the National Cancer Institute (...

Sana’s cell therapy may be ‘transformative cure’ for type 1 diabetes: analysts

Sana Biotechnology has shared early data for its investigational allogeneic cell therapy being studied in one patient with type 1 diabetes, sending the company’s share price up by about 200%. The data “pave the way for a potentially transformative cure,” for a disease that affects more than 1.7...

Aer Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Fexlamose in Chronic Obstructive Pulmonary Disease

Study AER-01-002 uses a novel and precision imaging strategy to enroll 100 mucus plug-high chronic obstructive pulmonary disease (COPD) patients AER-01-002 is well-powered to determine if 28-days of once-daily dosing of fexlamose is safe and improves lung function Fexlamose has been shown in Phase...

ScaleReady awards a G-Rex® Grant to Moonlight Bio

ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady, today announced that Moonlight Bio has been awarded a G-Rex® Grant. Moonlight Bio's G-Rex® Grant will expedite process development and IND-enabling studies of their lead CAR T cell...

Alessa Therapeutics Announces Closing $15M Seed Financing

Alessa Therapeutics, a clinical-stage drug development company pioneering an innovative and proprietary localized drug delivery technology for the early interception of cancer and other diseases, announced the closing of a $15M seed financing led by Mission BioCapital joined by Johnson &...

Chroma Medicine and Nvelop Therapeutics Unite to Form nChroma Bio, Securing $75 Million to Accelerate Genetic Medicines

Chroma Medicine and Nvelop Therapeutics today announced their merger and subsequent launch of nChroma Bio (“nChroma” or “the company”) to redefine the future of genetic medicines. nChroma brings together potent epigenetic editing plus non-viral, programmable delivery to address key limitations in...

Vevo Therapeutics Partners with the Parse Biosciences GigaLab to Generate 100M Cell Atlas for AI Powered Drug Discovery

Parse Biosciences, a leading provider of accessible and scalable single-cell sequencing solutions, today announced the generation of the world’s largest single-cell dataset to date, totaling 100 million cells. This impressive milestone was achieved in just one month using Parse Biosciences’ GigaLab...

Delve Bio Announces Launch of its Groundbreaking Genomic Infectious Disease Test, Delve Detect

Delve Bio, a pioneer in metagenomic sequencing, today announced the commercial launch of